Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Braz. j. microbiol ; 46(4): 1119-1124, Oct.-Dec. 2015. tab
Article Dans Anglais | LILACS | ID: lil-769658

Résumé

Abstract Acinetobacter baumannii is a frequently isolated etiologic agent of nosocomial infections, especially in intensive care units. With the increase in multi-drug resistance of A. baumannii isolates, finding appropriate treatment alternatives for infections caused by these bacteria has become more difficult, and available alternate treatments include the use of older antibiotics such as colistin or a combination of antibiotics. The current study aimed to evaluate the in vitro efficacy of various antibiotic combinations against multi-drug resistant A. baumannii strains. Thirty multi-drug and carbapenem resistant A. baumannii strains isolated at the Ankara Training and Research Hospital between June 2011 and June 2012 were used in the study. Antibiotic susceptibility tests and species-level identification were performed using conventional methods and the VITEK 2 system. The effects of meropenem, ciprofloxacin, amikacin, tigecycline, and colistin alone and in combination with sulbactam against the isolates were studied using Etest (bioMérieux) in Mueller-Hinton agar medium. Fractional inhibitory concentration index (FIC) was used to determine the efficacy of the various combinations. While all combinations showed a predominant indifferent effect, a synergistic effect was also observed in 4 of the 5 combinations. Synergy was demonstrated in 43% of the isolates with the meropenem-sulbactam combination, in 27% of the isolates with tigecycline-sulbactam, and in 17% of the isolates with colistin-sulbactam and amikacin-sulbactam. No synergy was detected with the sulbactam-ciprofloxacin combination and antagonism was detected only in the sulbactam-colistin combination (6.66% of the isolates). Antibiotic combinations can be used as an alternative treatment approach in multi-drug resistant A. baumannii infections.


Sujets)
Infections à Acinetobacter/effets des médicaments et des substances chimiques , Infections à Acinetobacter/croissance et développement , Infections à Acinetobacter/microbiologie , Infections à Acinetobacter/pharmacologie , Acinetobacter baumannii/effets des médicaments et des substances chimiques , Acinetobacter baumannii/croissance et développement , Acinetobacter baumannii/microbiologie , Acinetobacter baumannii/pharmacologie , Antibactériens/effets des médicaments et des substances chimiques , Antibactériens/croissance et développement , Antibactériens/microbiologie , Antibactériens/pharmacologie , Multirésistance bactérienne aux médicaments/effets des médicaments et des substances chimiques , Multirésistance bactérienne aux médicaments/croissance et développement , Multirésistance bactérienne aux médicaments/microbiologie , Multirésistance bactérienne aux médicaments/pharmacologie , Synergie des médicaments/effets des médicaments et des substances chimiques , Synergie des médicaments/croissance et développement , Synergie des médicaments/microbiologie , Synergie des médicaments/pharmacologie , Humains/effets des médicaments et des substances chimiques , Humains/croissance et développement , Humains/microbiologie , Humains/pharmacologie , Tests de sensibilité microbienne/effets des médicaments et des substances chimiques , Tests de sensibilité microbienne/croissance et développement , Tests de sensibilité microbienne/microbiologie , Tests de sensibilité microbienne/pharmacologie , Sulbactam/effets des médicaments et des substances chimiques , Sulbactam/croissance et développement , Sulbactam/microbiologie , Sulbactam/pharmacologie
SÉLECTION CITATIONS
Détails de la recherche